Concepts (256)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| DNA Repair | 14 | 2022 | 181 | 4.300 |
Why?
|
| Breast Neoplasms | 16 | 2022 | 1426 | 2.050 |
Why?
|
| Skin Neoplasms | 4 | 2011 | 151 | 1.060 |
Why?
|
| Carcinoma, Basal Cell | 4 | 2011 | 20 | 1.030 |
Why?
|
| DNA, Neoplasm | 2 | 2021 | 86 | 0.960 |
Why?
|
| Lymphocytes | 2 | 2020 | 116 | 0.790 |
Why?
|
| Overweight | 1 | 2022 | 233 | 0.750 |
Why?
|
| DNA Methylation | 3 | 2021 | 301 | 0.720 |
Why?
|
| Vitamin D | 1 | 2020 | 176 | 0.660 |
Why?
|
| Case-Control Studies | 10 | 2018 | 1056 | 0.650 |
Why?
|
| DNA Damage | 3 | 2012 | 341 | 0.650 |
Why?
|
| Carcinoma, Squamous Cell | 3 | 2011 | 176 | 0.640 |
Why?
|
| MicroRNAs | 2 | 2023 | 386 | 0.560 |
Why?
|
| Receptors, Estrogen | 1 | 2016 | 145 | 0.520 |
Why?
|
| Aged | 12 | 2021 | 6448 | 0.500 |
Why?
|
| Middle Aged | 15 | 2021 | 9642 | 0.470 |
Why?
|
| Gene Expression | 1 | 2016 | 639 | 0.460 |
Why?
|
| Epigenesis, Genetic | 3 | 2021 | 198 | 0.450 |
Why?
|
| Neoplasm Staging | 4 | 2021 | 269 | 0.450 |
Why?
|
| Gene Expression Regulation, Neoplastic | 3 | 2021 | 781 | 0.450 |
Why?
|
| BRCA2 Protein | 4 | 2019 | 37 | 0.450 |
Why?
|
| Xeroderma Pigmentosum Group D Protein | 2 | 2013 | 3 | 0.440 |
Why?
|
| Adult | 13 | 2022 | 11034 | 0.440 |
Why?
|
| Female | 22 | 2022 | 19873 | 0.440 |
Why?
|
| Humans | 35 | 2023 | 34853 | 0.430 |
Why?
|
| Fanconi Anemia | 1 | 2011 | 12 | 0.410 |
Why?
|
| Risk Factors | 7 | 2022 | 3414 | 0.380 |
Why?
|
| Melanoma | 1 | 2011 | 91 | 0.370 |
Why?
|
| Germ-Line Mutation | 2 | 2019 | 51 | 0.360 |
Why?
|
| Ultraviolet Rays | 2 | 2011 | 116 | 0.340 |
Why?
|
| Up-Regulation | 1 | 2011 | 490 | 0.340 |
Why?
|
| Antineoplastic Agents | 6 | 2014 | 756 | 0.340 |
Why?
|
| Organometallic Compounds | 4 | 2010 | 68 | 0.330 |
Why?
|
| Puerto Rico | 10 | 2021 | 1352 | 0.330 |
Why?
|
| Genes, p53 | 1 | 2007 | 24 | 0.320 |
Why?
|
| Receptors, Cell Surface | 1 | 2007 | 135 | 0.300 |
Why?
|
| BRCA1 Protein | 3 | 2019 | 47 | 0.290 |
Why?
|
| Logistic Models | 3 | 2016 | 894 | 0.250 |
Why?
|
| Carcinoma, Ductal, Breast | 1 | 2004 | 32 | 0.240 |
Why?
|
| Ferrous Compounds | 2 | 2014 | 20 | 0.230 |
Why?
|
| Genetic Variation | 2 | 2018 | 328 | 0.220 |
Why?
|
| Prostatic Neoplasms | 2 | 2021 | 794 | 0.220 |
Why?
|
| Oxocins | 1 | 2002 | 3 | 0.210 |
Why?
|
| Ciguatera Poisoning | 1 | 2002 | 5 | 0.210 |
Why?
|
| Foodborne Diseases | 1 | 2002 | 22 | 0.210 |
Why?
|
| Acute Disease | 1 | 2002 | 141 | 0.210 |
Why?
|
| Biological Clocks | 1 | 2021 | 51 | 0.200 |
Why?
|
| Genetic Predisposition to Disease | 6 | 2019 | 528 | 0.190 |
Why?
|
| DNA Breaks, Double-Stranded | 1 | 2020 | 34 | 0.180 |
Why?
|
| Norepinephrine | 1 | 2020 | 107 | 0.180 |
Why?
|
| Oncogenes | 1 | 2019 | 43 | 0.180 |
Why?
|
| Triamcinolone Acetonide | 1 | 2019 | 2 | 0.180 |
Why?
|
| Keloid | 1 | 2019 | 3 | 0.180 |
Why?
|
| Aged, 80 and over | 4 | 2014 | 2333 | 0.180 |
Why?
|
| Neuromuscular Agents | 1 | 2019 | 4 | 0.170 |
Why?
|
| Body Mass Index | 1 | 2022 | 775 | 0.170 |
Why?
|
| Ovarian Neoplasms | 2 | 2020 | 303 | 0.170 |
Why?
|
| Glucocorticoids | 1 | 2019 | 80 | 0.170 |
Why?
|
| Genes, BRCA2 | 1 | 2018 | 6 | 0.160 |
Why?
|
| Young Adult | 3 | 2019 | 4012 | 0.150 |
Why?
|
| Male | 12 | 2021 | 18870 | 0.140 |
Why?
|
| Regression Analysis | 1 | 2017 | 429 | 0.140 |
Why?
|
| Receptors, Progesterone | 1 | 2016 | 78 | 0.140 |
Why?
|
| Genetic Testing | 1 | 2015 | 71 | 0.130 |
Why?
|
| Subcellular Fractions | 1 | 2005 | 72 | 0.130 |
Why?
|
| Receptor, erbB-2 | 1 | 2016 | 122 | 0.130 |
Why?
|
| Photosensitizing Agents | 1 | 2005 | 47 | 0.130 |
Why?
|
| Obesity | 1 | 2022 | 965 | 0.130 |
Why?
|
| Porphyrins | 1 | 2005 | 53 | 0.130 |
Why?
|
| DNA-Binding Proteins | 2 | 2019 | 522 | 0.130 |
Why?
|
| Fluorescent Dyes | 1 | 2005 | 173 | 0.120 |
Why?
|
| Nerve Growth Factors | 1 | 2014 | 33 | 0.120 |
Why?
|
| Pilot Projects | 3 | 2021 | 628 | 0.120 |
Why?
|
| Regional Health Planning | 1 | 2013 | 14 | 0.120 |
Why?
|
| Tacrolimus Binding Proteins | 1 | 2014 | 41 | 0.120 |
Why?
|
| DNA Repair Enzymes | 1 | 2013 | 20 | 0.120 |
Why?
|
| Phenotype | 1 | 2016 | 650 | 0.120 |
Why?
|
| Minority Health | 1 | 2013 | 81 | 0.120 |
Why?
|
| ROC Curve | 1 | 2012 | 138 | 0.110 |
Why?
|
| Reactive Oxygen Species | 1 | 2014 | 416 | 0.110 |
Why?
|
| Genetic Markers | 1 | 2012 | 118 | 0.110 |
Why?
|
| Promoter Regions, Genetic | 1 | 2014 | 484 | 0.100 |
Why?
|
| Ergocalciferols | 1 | 2011 | 6 | 0.100 |
Why?
|
| Fanconi Anemia Complementation Group L Protein | 1 | 2011 | 2 | 0.100 |
Why?
|
| Fanconi Anemia Complementation Group C Protein | 1 | 2011 | 3 | 0.100 |
Why?
|
| Fanconi Anemia Complementation Group Proteins | 1 | 2011 | 10 | 0.100 |
Why?
|
| Fanconi Anemia Complementation Group D2 Protein | 1 | 2011 | 9 | 0.100 |
Why?
|
| CpG Islands | 2 | 2021 | 91 | 0.100 |
Why?
|
| Apoproteins | 2 | 2008 | 14 | 0.100 |
Why?
|
| Sensitivity and Specificity | 1 | 2012 | 555 | 0.100 |
Why?
|
| Societies, Scientific | 1 | 2010 | 8 | 0.100 |
Why?
|
| Transferrin | 2 | 2008 | 31 | 0.100 |
Why?
|
| Oligonucleotide Array Sequence Analysis | 1 | 2011 | 298 | 0.090 |
Why?
|
| Mutagens | 1 | 2010 | 66 | 0.090 |
Why?
|
| Steroids | 1 | 2010 | 43 | 0.090 |
Why?
|
| Gonadal Steroid Hormones | 1 | 2010 | 50 | 0.090 |
Why?
|
| Estrogens | 1 | 2011 | 190 | 0.090 |
Why?
|
| Molybdenum | 1 | 2009 | 14 | 0.090 |
Why?
|
| Polymorphism, Single Nucleotide | 1 | 2013 | 638 | 0.090 |
Why?
|
| Reproducibility of Results | 1 | 2012 | 901 | 0.090 |
Why?
|
| Health Services Accessibility | 1 | 2013 | 531 | 0.090 |
Why?
|
| Colonic Neoplasms | 2 | 2011 | 181 | 0.090 |
Why?
|
| Healthcare Disparities | 1 | 2013 | 446 | 0.090 |
Why?
|
| Chelating Agents | 1 | 2009 | 53 | 0.090 |
Why?
|
| Serum Albumin | 1 | 2009 | 49 | 0.090 |
Why?
|
| Cell Line, Tumor | 5 | 2020 | 2128 | 0.090 |
Why?
|
| Epinephrine | 2 | 2020 | 35 | 0.080 |
Why?
|
| Titanium | 1 | 2008 | 34 | 0.080 |
Why?
|
| Odds Ratio | 2 | 2013 | 517 | 0.080 |
Why?
|
| Age of Onset | 1 | 2007 | 98 | 0.080 |
Why?
|
| Health Status Disparities | 1 | 2013 | 583 | 0.080 |
Why?
|
| Dose-Response Relationship, Drug | 3 | 2009 | 984 | 0.080 |
Why?
|
| Models, Molecular | 3 | 2019 | 751 | 0.070 |
Why?
|
| Luciferases | 2 | 2004 | 62 | 0.070 |
Why?
|
| Risk Assessment | 2 | 2012 | 727 | 0.070 |
Why?
|
| Time Factors | 4 | 2007 | 1681 | 0.070 |
Why?
|
| Dose-Response Relationship, Radiation | 1 | 2004 | 37 | 0.070 |
Why?
|
| Epidemiologic Studies | 1 | 2004 | 31 | 0.060 |
Why?
|
| Neoplasms | 1 | 2013 | 1033 | 0.060 |
Why?
|
| Genetics, Population | 2 | 2015 | 66 | 0.060 |
Why?
|
| Cell Proliferation | 1 | 2009 | 1149 | 0.060 |
Why?
|
| Neoplasms, Multiple Primary | 1 | 2003 | 14 | 0.060 |
Why?
|
| Latin America | 2 | 2015 | 41 | 0.060 |
Why?
|
| Age Distribution | 1 | 2003 | 223 | 0.060 |
Why?
|
| Sex Distribution | 1 | 2003 | 212 | 0.060 |
Why?
|
| Retrospective Studies | 2 | 2012 | 1961 | 0.060 |
Why?
|
| Ligands | 3 | 2009 | 317 | 0.060 |
Why?
|
| Copper Sulfate | 1 | 2002 | 5 | 0.050 |
Why?
|
| Ciguatoxins | 1 | 2002 | 3 | 0.050 |
Why?
|
| Marine Toxins | 1 | 2002 | 14 | 0.050 |
Why?
|
| Tropical Climate | 1 | 2002 | 21 | 0.050 |
Why?
|
| Ascorbic Acid | 1 | 2002 | 63 | 0.050 |
Why?
|
| Incidence | 1 | 2004 | 882 | 0.050 |
Why?
|
| Argentina | 2 | 2012 | 11 | 0.050 |
Why?
|
| Neurotoxins | 1 | 2002 | 52 | 0.050 |
Why?
|
| Biological Assay | 1 | 2002 | 56 | 0.050 |
Why?
|
| Gastrointestinal Diseases | 1 | 2002 | 41 | 0.050 |
Why?
|
| Structure-Activity Relationship | 2 | 2014 | 376 | 0.050 |
Why?
|
| Genotype | 2 | 2013 | 641 | 0.050 |
Why?
|
| DNA Glycosylases | 1 | 2019 | 16 | 0.050 |
Why?
|
| Cisplatin | 1 | 2020 | 70 | 0.050 |
Why?
|
| Point Mutation | 1 | 2019 | 88 | 0.040 |
Why?
|
| Mutation, Missense | 1 | 2019 | 80 | 0.040 |
Why?
|
| Mutation | 2 | 2015 | 1023 | 0.040 |
Why?
|
| Pruritus | 1 | 2019 | 3 | 0.040 |
Why?
|
| Injections, Intralesional | 1 | 2019 | 11 | 0.040 |
Why?
|
| Spectrum Analysis | 2 | 2010 | 51 | 0.040 |
Why?
|
| Molecular Conformation | 2 | 2010 | 150 | 0.040 |
Why?
|
| Histones | 1 | 2020 | 177 | 0.040 |
Why?
|
| Animals | 7 | 2010 | 14307 | 0.040 |
Why?
|
| Disease Progression | 1 | 2021 | 580 | 0.040 |
Why?
|
| Drug Therapy, Combination | 1 | 2019 | 217 | 0.040 |
Why?
|
| Double-Blind Method | 1 | 2019 | 269 | 0.040 |
Why?
|
| Infant | 1 | 2002 | 1014 | 0.040 |
Why?
|
| Introns | 1 | 2018 | 67 | 0.040 |
Why?
|
| Child, Preschool | 1 | 2002 | 1318 | 0.040 |
Why?
|
| Gene Expression Profiling | 1 | 2021 | 600 | 0.040 |
Why?
|
| Hexanols | 1 | 1975 | 2 | 0.040 |
Why?
|
| Pain | 1 | 2019 | 249 | 0.030 |
Why?
|
| Caribbean Region | 1 | 2015 | 63 | 0.030 |
Why?
|
| Adrenergic alpha-Antagonists | 1 | 1975 | 29 | 0.030 |
Why?
|
| Acetylcholinesterase | 1 | 1975 | 53 | 0.030 |
Why?
|
| Aminoacridines | 1 | 2005 | 1 | 0.030 |
Why?
|
| Acridine Orange | 1 | 2005 | 2 | 0.030 |
Why?
|
| Adrenergic beta-Antagonists | 1 | 1975 | 50 | 0.030 |
Why?
|
| Carbocyanines | 1 | 2005 | 14 | 0.030 |
Why?
|
| Gene Frequency | 1 | 2015 | 155 | 0.030 |
Why?
|
| Cardiolipins | 1 | 2005 | 11 | 0.030 |
Why?
|
| Choline | 1 | 1975 | 57 | 0.030 |
Why?
|
| Micronucleus Tests | 1 | 2014 | 10 | 0.030 |
Why?
|
| Fluorescence Resonance Energy Transfer | 1 | 2005 | 50 | 0.030 |
Why?
|
| Staining and Labeling | 1 | 2005 | 100 | 0.030 |
Why?
|
| Treatment Outcome | 1 | 2019 | 1349 | 0.030 |
Why?
|
| Adenosine Triphosphate | 1 | 1975 | 180 | 0.030 |
Why?
|
| Endoplasmic Reticulum | 1 | 2005 | 101 | 0.030 |
Why?
|
| Adipose Tissue | 1 | 1975 | 167 | 0.030 |
Why?
|
| Child | 1 | 2002 | 2875 | 0.030 |
Why?
|
| Southeastern United States | 1 | 2013 | 48 | 0.030 |
Why?
|
| Interinstitutional Relations | 1 | 2013 | 35 | 0.030 |
Why?
|
| Community Networks | 1 | 2013 | 98 | 0.030 |
Why?
|
| Protein Binding | 2 | 2011 | 913 | 0.030 |
Why?
|
| Needs Assessment | 1 | 2013 | 159 | 0.030 |
Why?
|
| Adolescent | 2 | 2002 | 5035 | 0.030 |
Why?
|
| Heterozygote | 1 | 2012 | 91 | 0.030 |
Why?
|
| Chromosome Mapping | 1 | 2012 | 159 | 0.030 |
Why?
|
| Polymerase Chain Reaction | 1 | 2013 | 430 | 0.030 |
Why?
|
| Insurance Coverage | 1 | 2012 | 99 | 0.030 |
Why?
|
| Mitochondria | 1 | 2005 | 454 | 0.030 |
Why?
|
| Insurance, Health | 1 | 2012 | 120 | 0.030 |
Why?
|
| Estrogen Receptor alpha | 1 | 2011 | 105 | 0.020 |
Why?
|
| Prognosis | 1 | 2013 | 707 | 0.020 |
Why?
|
| Brazil | 1 | 2010 | 66 | 0.020 |
Why?
|
| Oxygen | 2 | 2009 | 193 | 0.020 |
Why?
|
| Quantum Theory | 1 | 2010 | 76 | 0.020 |
Why?
|
| Socioeconomic Factors | 1 | 2013 | 1003 | 0.020 |
Why?
|
| Titrimetry | 1 | 2009 | 7 | 0.020 |
Why?
|
| Electrochemical Techniques | 1 | 2009 | 22 | 0.020 |
Why?
|
| Spectrophotometry | 1 | 2009 | 71 | 0.020 |
Why?
|
| Environment | 1 | 2010 | 130 | 0.020 |
Why?
|
| Solubility | 1 | 2009 | 115 | 0.020 |
Why?
|
| Spectrometry, Mass, Electrospray Ionization | 1 | 2009 | 129 | 0.020 |
Why?
|
| Pregnancy | 1 | 2013 | 1503 | 0.020 |
Why?
|
| Tetrazolium Salts | 1 | 2008 | 36 | 0.020 |
Why?
|
| HT29 Cells | 1 | 2008 | 40 | 0.020 |
Why?
|
| Rats | 4 | 1975 | 3261 | 0.020 |
Why?
|
| Solutions | 1 | 2008 | 60 | 0.020 |
Why?
|
| Spectrophotometry, Ultraviolet | 1 | 2008 | 94 | 0.020 |
Why?
|
| Drug Stability | 1 | 2008 | 110 | 0.020 |
Why?
|
| Thiazoles | 1 | 2008 | 71 | 0.020 |
Why?
|
| Molecular Structure | 1 | 2009 | 467 | 0.020 |
Why?
|
| Chemistry, Pharmaceutical | 1 | 2007 | 65 | 0.020 |
Why?
|
| Magnetic Resonance Spectroscopy | 1 | 2008 | 281 | 0.020 |
Why?
|
| Tetanus | 1 | 1976 | 3 | 0.020 |
Why?
|
| Methyltyrosines | 1 | 1975 | 1 | 0.020 |
Why?
|
| Cell Survival | 1 | 2009 | 818 | 0.020 |
Why?
|
| Trypanosoma | 1 | 1975 | 8 | 0.020 |
Why?
|
| Adrenalectomy | 1 | 1975 | 24 | 0.020 |
Why?
|
| Models, Chemical | 1 | 2007 | 201 | 0.020 |
Why?
|
| United States | 1 | 2015 | 3894 | 0.020 |
Why?
|
| Digitoxin | 1 | 1975 | 7 | 0.020 |
Why?
|
| Respiration | 1 | 1976 | 49 | 0.020 |
Why?
|
| Carbon Dioxide | 1 | 1976 | 78 | 0.020 |
Why?
|
| Microsomes, Liver | 1 | 1975 | 69 | 0.020 |
Why?
|
| Corpus Striatum | 1 | 1975 | 99 | 0.020 |
Why?
|
| Dopamine | 1 | 1975 | 232 | 0.020 |
Why?
|
| Drug Screening Assays, Antitumor | 1 | 2002 | 107 | 0.010 |
Why?
|
| Cell Division | 1 | 2002 | 296 | 0.010 |
Why?
|
| Tumor Cells, Cultured | 1 | 2002 | 480 | 0.010 |
Why?
|
| Hydrogen-Ion Concentration | 2 | 1976 | 342 | 0.010 |
Why?
|
| Osmolar Concentration | 1 | 1975 | 55 | 0.010 |
Why?
|
| Phenoxybenzamine | 1 | 1975 | 2 | 0.010 |
Why?
|
| Phosphorus Radioisotopes | 1 | 1975 | 9 | 0.010 |
Why?
|
| Hexokinase | 1 | 1975 | 9 | 0.010 |
Why?
|
| Mathematics | 1 | 1975 | 42 | 0.010 |
Why?
|
| Propranolol | 1 | 1975 | 17 | 0.010 |
Why?
|
| Sodium Chloride | 1 | 1975 | 52 | 0.010 |
Why?
|
| Oxygen Consumption | 1 | 1975 | 98 | 0.010 |
Why?
|
| Phosphorus | 1 | 1975 | 64 | 0.010 |
Why?
|
| Kinetics | 1 | 1975 | 650 | 0.010 |
Why?
|
| Binding Sites | 1 | 1975 | 597 | 0.010 |
Why?
|
| Partial Pressure | 1 | 1976 | 7 | 0.000 |
Why?
|
| Benserazide | 1 | 1975 | 1 | 0.000 |
Why?
|
| Brocresine | 1 | 1975 | 1 | 0.000 |
Why?
|
| Liver Glycogen | 1 | 1975 | 1 | 0.000 |
Why?
|
| p-Hydroxyamphetamine | 1 | 1975 | 1 | 0.000 |
Why?
|
| Homovanillic Acid | 1 | 1975 | 10 | 0.000 |
Why?
|
| 3,4-Dihydroxyphenylacetic Acid | 1 | 1975 | 27 | 0.000 |
Why?
|
| Biological Transport, Active | 1 | 1975 | 25 | 0.000 |
Why?
|
| Blood | 1 | 1976 | 32 | 0.000 |
Why?
|
| Digitoxigenin | 1 | 1975 | 4 | 0.000 |
Why?
|
| Hydroxylation | 1 | 1975 | 14 | 0.000 |
Why?
|
| NADP | 1 | 1975 | 24 | 0.000 |
Why?
|
| Chromatography, Thin Layer | 1 | 1975 | 37 | 0.000 |
Why?
|
| Tyrosine 3-Monooxygenase | 1 | 1975 | 72 | 0.000 |
Why?
|
| Tyrosine | 1 | 1975 | 109 | 0.000 |
Why?
|
| Glucose | 1 | 1975 | 217 | 0.000 |
Why?
|